BioAge Labs, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
BIOA$5.78+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Unaudited Conde nsed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2026 | 2025 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(81,854) | $(54,662) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 13,169 | 8,969 |
| Depreciation expense | 213 | 144 |
| Non-cash interest expense | 12 | 156 |
| Non-cash lease expense | 126 | 115 |
| Gain from changes in fair value of warrants | (206) | (6) |
| Accretion of net investment discounts | (1,507) | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 204 | (515) |
| Prepaid expenses and other current assets | (5,920) | (1,481) |
| Other assets | 11 | 13 |
| Accounts payable | (768) | 3,095 |
| Accrued expenses and other current liabilities | 3,377 | (4,766) |
| Deferred revenue | (1,122) | (4,438) |
| Net cash used in operating activities | (74,265) | (53,376) |
| INVESTING ACTIVITIES | ||
| Purchase of property and equipment | (372) | (607) |
| Purchases of marketable securities | (344,863) | (114,431) |
| Maturities of marketable securities | 141,512 | 34,250 |
| Net cash used in investing activities | (203,723) | (80,788) |
| FINANCING ACTIVITIES | ||
| Proceeds from underwritten offering of common stock, net of underwriting discounts and commissions | 124,315 | — |
| Underwritten offering issuance costs paid | (758) | — |
| Proceeds from issuance of common stock through at-the-market facility, net of commissions | 15,852 | — |
| Issuance costs paid on at-the-market offering | (215) | — |
| Deferred offering costs paid | (102) | (44) |
| Term loan principal payments | (2,000) | (4,500) |
| Payment of term loan final fee for loan maturity | (660) | — |
| Proceeds from issuance of common shares under employee stock purchase plan | 98 | — |
| Proceeds from issuance of common shares upon stock option exercises | 5,233 | — |
| Net cash provided by (used in) financing activities | 141,763 | (4,544) |
| Effect of changes in exchange rate on cash and cash equivalents | 3 | (68) |
| Net decrease in cash and cash equivalents | (136,222) | (138,776) |
| Cash and cash equivalents at beginning of period | 188,888 | 354,349 |
| Cash and cash equivalents at end of period | $52,666 | $215,573 |
| Supplemental non-cash disclosure: | ||
| Deferred offering costs included in accounts payable and accrued expenses | $27 | $255 |
| Purchases of property and equipment in accounts payable and accrued expenses | $21 | $42 |
| Cash paid for interest | $46 | $526 |
| Right-of-use assets obtained in exchange for lease obligation | $— | $3,106 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.